FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WALTHER, T.
Right arrow Articles by SCHIRNER, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WALTHER, T.
Right arrow Articles by SCHIRNER, M.
(The FASEB Journal. 2003;17:2061-2067.)
© 2003 FASEB

Differential regulation of in vivo angiogenesis by angiotensin II receptors

THOMAS WALTHER#,1, ANDREAS MENRAD*, HANS-DIETER ORZECHOWSKI§, GERHARD SIEMEISTER*, MARTIN PAUL§ and MICHAEL SCHIRNER*

* Research Laboratories of Schering AG, Experimental Oncology, 13342 Berlin, Germany; and
# Department of Cardiology and Pneumology and
§ Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, 12200 Berlin, Germany

1Correspondence: Benjamin Franklin Medical Center, Department of Cardiology and Pneumology, Hindenburgdamm 30 D-12200 Berlin, Germany. E-mail: thomas.walther{at}ukbf.fu-berlin.de

Angiotensin II (ANG II), a key regulator of blood pressure and body fluid homeostasis, exerts mitogenic effects on endothelial cells. We therefore hypothesized that ANG II could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis. In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG II levels, elevated ANG II levels by transgenic overexpression of angiotensinogen (AOGEN), or in AT2 receptor-deficient mice. We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. However, the strong increase of angiogenesis in AOGEN-transgenic mice compared with mice with normal ANG II levels suggests additional stimulatory activity. We showed that the ANG II-induced stimulation of angiogenesis is linked to the AT2 receptor as an impaired induction of angiogenesis was obtained in AT2 receptor knockout mice. These findings provide the first evidence that the AT2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ANG II is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions.—Walther, W., Menrad, A., Orzechowski, H.-D., Siemeister, G., Paul, M., Schirner, M. Differential regulation of in vivo angiogenesis by angiotensin II receptors.


Key Words: alginate implant angiogenesis • angiotensin receptor AT1 • angiotensin receptor AT2




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Reed, C. Kolz, B. Potter, and P. Rocic
The Mechanistic Basis for the Disparate Effects of Angiotensin II on Coronary Collateral Growth
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 61 - 67.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Hu, A. Dandapat, and J. L Mehta
Angiotensin II Induces Capillary Formation From Endothelial Cells Via the LOX-1 Dependent Redox-Sensitive Pathway
Hypertension, November 1, 2007; 50(5): 952 - 957.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer
Nonclassic Endogenous Novel Regulators of Angiogenesis
Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
V. C. Munk, L. Sanchez de Miguel, M. Petrimpol, N. Butz, A. Banfi, U. Eriksson, L. Hein, R. Humar, and E. J. Battegay
Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway
Hypertension, May 1, 2007; 49(5): 1178 - 1185.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Rakusan, Z. Chvojkova, P. Oliviero, I. Ostadalova, F. Kolar, C. Chassagne, J.-L. Samuel, and B. Ostadal
ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1237 - H1244.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Feihl, L. Liaudet, B. Waeber, and B. I. Levy
Hypertension: A Disease of the Microcirculation?
Hypertension, December 1, 2006; 48(6): 1012 - 1017.
[Full Text] [PDF]


Home page
HypertensionHome page
T. A. Barker, M. P. Massett, V. A. Korshunov, A. M. Mohan, A. J. Kennedy, and B. C. Berk
Angiotensin II Type 2 Receptor Expression After Vascular Injury: Differing Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade
Hypertension, November 1, 2006; 48(5): 942 - 949.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. D'Amore, M. J. Black, and W. G. Thomas
The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy
Hypertension, December 1, 2005; 46(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Gonzalez-Zuloeta Ladd, A. Arias Vasquez, F. A. Sayed-Tabatabaei, J.W. Coebergh, A. Hofman, O. Njajou, B. Stricker, and C. van Duijn
Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2143 - 2146.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. Zheng, I. M. Bird, D.-B. Chen, and R. R. Magness
Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide
J. Physiol., May 15, 2005; 565(1): 59 - 69.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Rocken, U. Lendeckel, J. Dierkes, S. Westphal, S. Carl-McGrath, B. Peters, S. Kruger, P. Malfertheiner, A. Roessner, and M. P.A. Ebert
The Number of Lymph Node Metastases in Gastric Cancer Correlates with the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism
Clin. Cancer Res., April 1, 2005; 11(7): 2526 - 2530.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Watanabe, T. A. Barker, and B. C. Berk
Angiotensin II and the Endothelium: Diverse Signals and Effects
Hypertension, February 1, 2005; 45(2): 163 - 169.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
Y.-Y. Hsieh, C.-C. Chang, F.-J. Tsai, C.-M. Hsu, C.-C. Lin, and C.-H. Tsai
Angiotensin I-converting enzyme ACE 2350*G and ACE-240*T-related genotypes and alleles are associated with higher susceptibility to endometriosis
Mol. Hum. Reprod., January 1, 2005; 11(1): 11 - 14.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. H.P. Hilgers, P. M.H. Schiffers, W. M. Aartsen, G. E. Fazzi, J. F.M. Smits, and J. G.R. De Mey
Tissue Angiotensin-Converting Enzyme in Imposed and Physiological Flow-Related Arterial Remodeling in Mice
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 892 - 897.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Ichiki
Role of Renin Angiotensin System in Angiogenesis: It Is Still Elusive
Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 622 - 624.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by The Federation of American Societies for Experimental Biology.